Trial Site Detail

 

Drug:
AUY922
Trial:
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.
Conditions: Solid Tumors
Trial Status:
Ongoing, but not recruiting

 

David Geffen School of Medicine at UCLA

10833 Le Conte Ave     
Los Angeles , CA 90095
USA

 

Principal Investigator:
 Carolyn Britten, M.D.
Contact:
 CBritten@mednet.ucla.edu 310-825-5268
Activation Status of this Site:
 Closed
Notes about this Site:
David Geffen School of Medicine at UCLA Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.